查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1801228

2025 年至 2033 年良性前列腺增生治疗市场规模、份额、趋势及预测（依治疗类型及地区）

Benign Prostatic Hyperplasia Treatment Market Size, Share, Trends and Forecast by Treatment Type, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3个工作天内

价格

2024年，全球良性前列腺增生治疗市场规模达125亿美元。展望未来， IMARC Group预测，到2033年，该市场规模将达到185亿美元，2025-2033年期间的复合年增长率为4.4%。目前，北美占据市场主导地位，2024年将占据超过34.8%的市场。市场成长的驱动力包括老年男性良性前列腺增生（BPH）盛行率的上升、微创手术的进步以及药物製剂的改进。雷射疗法和联合治疗的创新进一步改善了患者的治疗效果，从而增加了良性前列腺增生治疗市场的份额。

良性摄护腺增生 (BPH) 治疗市场的主要驱动因素包括老年男性族群中 BPH 盛行率的上升、泌尿健康意识的增强以及微创治疗方案的进步。由于 BPH 对生活品质（包括泌尿系统症状和併发症）的影响，对有效疗法的需求日益增长。包括雷射疗法、改进的药物配方和联合用药在内的创新也促进了市场的成长，同时，已开发地区医疗保健可及性的提高以及优惠的报销政策也促进了市场的成长。例如，2024 年 9 月，皇家萨里郡 NHS 基金会信託推出了 EchoLaser 治疗良性前列腺增生，这种疾病影响着约 50% 的 50 岁以上男性。这项由前列腺计画慈善机构资助的微创手术可快速恢復，副作用极小，进而改善患者的生活品质并减少住院时间。这些进步正在为良性前列腺增生治疗市场创造一个积极的前景。

美国良性前列腺增生 (BPH) 治疗市场的主要驱动力是老年男性群体中 BPH 的高盛行率以及人们对泌尿系统健康的认识不断提高。雷射疗法和前列腺动脉栓塞术等微创手术的进展也因其效率高和恢復时间短而广受欢迎。例如，2023 年 7 月，波特兰基督復临安息日会推出了水消融疗法 (Aquablation Therapy)，这是一种利用水和机器人精准治疗良性前列腺增生 (BPH) 的微创疗法。这种创新疗法为男性治疗摄护腺肥大症状提供了新的选择。此外，药物和合併疗法的改进也扩大了治疗选择的范围。这进一步反映了美国良性前列腺增生治疗市场的主要趋势之一。

良性摄护腺增生治疗市场趋势：

转向微创手术

微创手术在良性前列腺增生的治疗中正日益普及。根据美国国立卫生研究院 (NIH) 的数据，估计约有 30% 的中度至重度前列腺增生 (BPH) 症状男性会接受某种形式的微创治疗。这些技术包括雷射治疗、经尿道摄护腺切除术 (TUMT) 和经尿道摄护腺切除术 (TURP)。这些技术已被证实有效且恢復时间短，因此深受患者和医生的青睐。这些手术确保治疗精准，对周围组织的损伤最小，从而减少出血或感染等併发症。此外，与传统的开放性手术相比，患者疼痛减轻，恢復正常活动的速度也更快。这与医疗保健行业向微创门诊服务发展的整体趋势相契合。钬雷射剜除术和绿光雷射治疗等技术的蓬勃发展进一步推动了市场的变革，如今，对于那些不愿长期住院或接受侵入性手术的患者来说，他们可以选择其他治疗方案。随着这些手术的接受度不断提高，对良性摄护腺增生治疗市场的需求也将逐渐增加。

先进药物疗法的出现

随着新型药物疗法的出现，良性前列腺增生 (BPH) 的治疗模式正在发生翻天覆地的变化。新型药物和联合疗法旨在更好地控制症状并减少副作用。根据美国国家糖尿病、消化和肾臟疾病研究所 (NIDDK) 的数据，51 至 60 岁男性中近 50% 患有良性前列腺增生 (BPH)，80 岁以上男性中高达 90% 患有 BPH，因此对药物治疗方案的需求日益增长。虽然 α 受体阻断剂和 5-α 还原酶抑制剂等传统疗法仍在发挥作用，但 α 受体阻断剂和 5-ARI 等先进药物疗法虽然是常用疗法，但也伴随着明显的副作用，例如头晕和性功能障碍。阿伏达特 (Avodart) 和西力士 (Cialis) 等药物的专利到期为仿製药带来了机会，它们提供了价格合理的替代品，并推动了药物治疗市场的成长。诸如PDE5抑制剂和新型双标靶疗法等药物的研发力度正在加大，它们为缓解症状提供了更全面的方案。这些先进的药物不仅可以治疗前列腺，还可以治疗勃起功能障碍－良性前列腺增生（BPH）的常见合併症。随着治疗方法的增多，这些患者可以享受个人化的、基于症状的治疗方案，从而更适合自己的健康状况和症状。另一个值得关注的趋势是将现有药物合併使用，以提高疗效并最大限度地减少副作用。随着生物製剂和基因疗法进入临床试验阶段，BPH的治疗模式将发生更显着的变化，为患者提供有效的长期治疗。

老年人口不断增加

全球老年人口是良性前列腺增生 (BPH) 治疗市场的主要成长动力。随着年龄增长，BPH 的发生率不断上升，且在 50 岁以上的男性中最为常见。从 1974 年到 2024 年，全球 65 岁人口比例几乎翻了一番，从 5.5% 上升到 10.3%。根据联合国人口统计数据，从 2024 年到 2074 年，这一数字预计将再次翻一番，达到 20.7%。同时，预计 80 岁及以上老年人口将超过目前的三倍。已开发地区的老年人口预计将大幅增加，从而显着扩大需要 BPH 治疗的人。这种人口结构变化可能会进一步加重医疗保健系统的压力，因为它需要有效且价格合理的治疗干预措施。全球人口老化正在刺激对 BPH 治疗的需求，而仿製药提供了低成本的选择，从而增加了患者的可及性和整体治疗销售。老年男性更容易患高血压和糖尿病等併发症。这些併发症进一步加剧了良性前列腺增生 (BPH) 的治疗难度，因此催生了客製化治疗方案的需求，旨在同时满足多种健康需求。老年人更容易受到 BPH 治疗副作用的影响，例如头晕和跌倒风险增加。随着人口老化，透过更安全的治疗方案最大限度地降低这些风险正成为医疗保健领域的首要任务。因此，製药和医疗保健公司一直在开发治疗 BPH 症状的药物，以全面提升患者（尤其是老年人）的生活品质。预计老龄化人口将继续增长，并透过增加对药物和手术治疗方案的需求来影响市场。

目录

第一章：前言

第二章：范围与方法

  • 研究目标
  • 利害关係人
  • 资料来源
    • 主要来源
    • 次要来源
  • 市场评估
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第三章：执行摘要

第四章：简介

第五章：全球良性前列腺增生治疗市场

  • 市场概览
  • 市场表现
  • COVID-19的影响
  • 市场预测

第六章：市场区隔：依治疗类型

  • 药物类别
    • 主要类型
      • 阿尔法受体阻断剂
      • 5-α还原酶抑制剂（5-ARI）
      • 磷酸二酯酶-5酶抑制剂
      • 其他的
  • 微创手术
    • 主要类型
      • 经尿道摄护腺切除术（TURP）
      • 经尿道摄护腺切开术（TUIP）
      • 经尿道微波热疗（TUMT）
      • 机器人手术
      • 前列腺尿道抬高术
      • 其他的
  • 雷射治疗
  • 其他的

第七章：市场区隔：依地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲

第 8 章：SWOT 分析

第九章：价值链分析

第 10 章：波特五力分析

第 11 章：价格分析

第 12 章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Abbott Laboratories
    • Allergan plc (AbbVie Inc.)
    • Asahi Kasei Corporation
    • Astellas Pharma Inc.
    • Boehringer Ingelheim GmbH (CH Boehringer Sohn AG & Ko. KG)
    • Boston Scientific Corporation
    • GlaxoSmithKline Plc
    • Pfizer Inc.
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112025A2898

The global benign prostatic hyperplasia treatment market size was valued at USD 12.5 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 18.5 Billion by 2033, exhibiting a CAGR of 4.4% during 2025-2033. North America currently dominates the market, holding a significant share of over 34.8% in 2024. The market is driven by the rising prevalence of BPH among aging men, advancements in minimally invasive procedures, and improved drug formulations. Innovations in laser therapies and combination treatments further enhance patient outcomes, increasing the benign prostatic hyperplasia treatment market share.

Key drivers in the benign prostatic hyperplasia (BPH) treatment market are the increasing prevalence of BPH among the aging male population, increasing awareness of urological health, and advances in minimally invasive treatment options. The demand for effective therapies is growing due to the impact of BPH on quality of life including urinary symptoms and complications. Innovations including laser therapy improved drug formulation and combinations also enhance growth in the market along with a rise in healthcare access as well as favorable reimbursement policies in developed regions. For instance, in September 2024, Royal Surrey NHS Foundation Trust introduced EchoLaser treatment for benign prostate enlargement a condition affecting about 50% of men over 50. Funded by the Prostate Project charity, this minimally invasive procedure allows rapid recovery and minimal side effects improving patient quality of life and reducing hospital stays. These advancements are creating a positive benign prostatic hyperplasia treatment market outlook.

The key drivers of the United States benign prostatic hyperplasia (BPH) treatment market are a high prevalence of BPH among the aging male population and increased awareness of urological health. Advances in minimally invasive procedures such as laser-based therapies and prostatic artery embolization also gained popularity based on their efficiency and quicker recovery times. For instance, in July 2023, Adventist Health Portland launched Aquablation Therapy a minimally invasive treatment for benign prostatic hyperplasia (BPH) using water and robotic precision. This innovative procedure represents a new option for men dealing with enlarged prostate symptoms. There is also availability of improved medications and combination therapies which boost the range of treatment options. This further represents one of the key benign prostatic hyperplasia treatment market trends in the United States.

Benign Prostatic Hyperplasia Treatment Market Trends:

Shift Toward Minimally Invasive Procedures

Minimally invasive procedures are being increasingly used for the treatment of benign prostatic hyperplasia. According to the U.S. National Institutes of Health (NIH), an estimated 30% of men with moderate to severe BPH symptoms undergo some form of minimally invasive treatment. Techniques include laser therapy, TUMT, and TURP. These are well accepted by both patients and physicians because they have been proven effective with minimal recovery time. Such procedures ensure the treatment is targeted with minimal damage to the surrounding tissues and, therefore, fewer complications in the form of bleeding or infection. In addition, the patients face less pain and faster return to regular activities than the traditional open surgeries. This is in tune with the general trends in the healthcare sector toward less invasive outpatient-focused services. Growth of technologies like Holmium laser enucleation and GreenLight laser therapy further fueled the shifting market, to the extent that, nowadays, alternatives are offered to the patients who do not want to undergo long durations of hospitalization or an invasive surgery. The growing acceptance of these procedures will lead to increased benign prostatic hyperplasia treatment market demand over the time.

Emergence of Advanced Drug Therapies

The landscape of BPH treatment is undergoing a sea change with the emergence of new pharmacological therapies. New classes of drugs and combination therapies aim at better symptom management with fewer side effects. According to the U.S. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), nearly 50% of men aged 51 to 60, and up to 90% of men over the age of 80, are affected by BPH, leading to a growing need for pharmacological treatment options. While traditional therapies like alpha-blockers and 5-alpha-reductase inhibitors continue to play their role, advanced drug therapies, such as alpha-blockers and 5-ARIs, are common treatments but come with notable side effects like dizziness and sexual dysfunction. The expiration of patents for drugs like Avodart and Cialis has opened opportunities for generics, providing affordable alternatives and driving market growth in drug treatments. Efforts are increasing to develop drugs like PDE5 inhibitors and novel dual-target therapies offer a more holistic approach to symptom relief. These advanced drugs treat not only the prostate but also erectile dysfunction, a common comorbidity for BPH. With more treatments available, these patients can take advantage of an individualized, symptom-based plan that is better suited to his or her health conditions and symptoms. Yet another trend to be seen includes combining existing medicines to improve potency and minimize harmful side effects. The landscape for BPH is set to change even more dramatically with the entry of biologics and gene therapies into clinical trials, providing the patient with effective long-term treatment.

Rising Geriatric Population

The global geriatric population is a major growth driver for the BPH treatment market. As people age, the incidence of BPH increases, and the condition is most common in men over the age of 50. From 1974 to 2024, the global proportion of individuals aged 65 nearly doubled, rising from 5.5% to 10.3%. From 2024 to 2074, the figure is set to double once more, reaching 20.7%, as per United Nations demographic estimates. At the same time, the population of individuals aged 80 and older is expected to exceed three times its current size. The elderly population is expected to increase substantially in developed regions, thus significantly expanding the pool of people requiring treatment for BPH. This demographic change is likely to further stress healthcare systems by demanding effective yet affordable treatment interventions. An aging global population is fueling demand for BPH treatments, with generics offering lower-cost options that increase patient access and overall treatment sales. Older males are more predisposed to co-morbidities like hypertension and diabetes. Such comorbidities further complicate the management of BPH, thus resulting in a driving force for tailormade regimens that meet multiple health demands at one time. Older adults are more vulnerable to side effects from BPH treatments, including dizziness and an increased risk of falls. With an aging population, minimizing these risks through safer treatments is becoming a priority in healthcare. Pharmaceutical and healthcare companies, therefore, have been developing drugs that treat the symptoms of BPH and generally enhance the quality of life for patients, especially the elderly. The aging population is projected to continue increasing and influence the market by enhancing the demand for pharmacological as well as surgical treatment options.

Benign Prostatic Hyperplasia Treatment Industry Segmentation:

Analysis by Treatment Type:

  • Drug Class
    • Alpha-Blockers
    • 5-Alpha-reductase Inhibitors (5-ARIs)
    • Phosphodiesterase-5 Enzyme Inhibitors
    • Others
  • Minimally Invasive Surgeries
    • Transurethral Resection of the Prostate (TURP)
    • Transurethral Incision of the Prostate (TUIP)
    • Transurethral Microwave Thermotherapy (TUMT)
    • Robotic Surgeries
    • Prostatic Urethral Lifts
    • Others
  • Laser Therapy
  • Others

Alpha-blockers account for the highest market benign prostatic hyperplasia treatment market share of the drug class category in BPH treatment. They are potent in offering symptomatic relief as quickly as possible. They are able to relax the muscles within the prostate and bladder neck to facilitate urine flow and reduce obstruction. Alpha-blockers are first-line drugs used for BPH due to their efficacy, availability and fewer side effects. Their ability to treat lower urinary tract symptoms without significantly altering prostate size makes them highly preferred by physicians. Increasing awareness, a growing aging male population and advancements in drug formulations further bolster the dominance of alpha-blockers in the BPH treatment market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 34.8%. North America is the most significant market of BPH treatments mainly driven by the sophisticated healthcare infrastructure within the region and the high incidence of BPH among aging males along with better awareness about urological health. The United States is a notable contributor to the market due to its large population of geriatrics and the use of advanced medical treatments which include minimally invasive procedures as well as newer drug therapies. Favorable reimbursement policies along with cutting-edge technologies like robotic-assisted surgeries and laser therapies continue to support benign prostatic hyperplasia treatment market growth. The key pharmaceutical and medical device manufacturers located in the region also stimulate continuous innovation. The growing importance of early diagnosis and proactive management of BPH symptoms further enhance North America's position as a global leader in the BPH treatment market.

Key Regional Takeaways:

United States Benign Prostatic Hyperplasia Treatment Market

In 2024, the United States captured 85.00% of revenue in the North American market. The U.S. BPH market is increasing due to a growing aging male population and the rising awareness of treatment options. According to the American Urological Association, about 50% of men over 50 years old have BPH or an enlarged prostate. Prevalence of BPH rises with age and, among men aged 60 to 69 years, it reaches 70% and among those over 70 years, 80%. Growth drivers are major effective medical therapies like 5-alpha reductase inhibitors and alpha blockers along with increasing surgical procedure adoption. Market growth is further facilitated by a shift towards telemedicine and home-based treatments that ensure broader accessibility to care. This market is, therefore attracting more prominent players like AbbVie and Astellas into their portfolios by focusing on innovation and patient-centric approaches.

Europe Benign Prostatic Hyperplasia Treatment Market

The BPH market in the region is rapidly growing due to an aging population and the increasing prevalence of prostate enlargement. The European Association of Urology states that benign prostatic hyperplasia, or BPH, affects 50% of men over the age of 50, while the condition progresses with age and reaches 70% in the age group 60 to 69 and 80% above 70. The awareness about BPH symptoms and the high number of new diagnoses are main drivers for this market growth. In Germany, the UK, and France, among others, they are widely accepting advanced treatments with surgical minimally invasive approaches, drug therapies, and combination therapies where better management could be achieved for patients. Boehringer Ingelheim and Janssen, the two leading pharmaceutical giants, lead in innovating by introducing new drug formulations that meet unmet needs in BPH care. Additionally, telehealth solutions are picking up the pace in offering consultation and allowing for an early diagnosis that would be a driving factor in this European market growth.

Asia Pacific Benign Prostatic Hyperplasia Treatment Market

The Asia Pacific BPH market is growing rapidly because of the increasing awareness, aging male population, and improved access to healthcare. Asian Development Bank says, by 2050, one in four people in Asia and the Pacific will be over 60 years of age. Projections indicate that this demographic shift, where the population of older persons aged over 60 in the region is expected to triple from 2010 until 2050, will attain nearly 1.3 billion. This demographic shift will create a significant demand for BPH treatments as well, given the rising prevalence of BPH with age. According to an industry report, the market size for BPH was USD 1.8 billion in 2023 in this region, primarily driven by an escalating diagnosis rate and government initiatives to enhance the healthcare system in these countries. The main momentum-setters in this region are Japan, South Korea, and China, with the state-of-the-art advancements in BPH treatment technology, including robotic surgeries and novel pharmacological interventions. Herbal and traditional treatments are also gaining relevance more in the region, mainly in the Indian subcontinent.

Latin America Benign Prostatic Hyperplasia Treatment Market

Latin American BPH is experiencing a rising tide, mainly fueled by the rise in the population's aging demographic and the resultant increase in the need for effective treatment. According to the Pan American Health Organization (PAHO), 20% of men older than 50 years in this region suffer from BPH. In addition, there is a demand for BPH-related treatments within Brazil and Mexico. BPH progresses with age in a majority of Latin American male populations. Cancer of the prostate is the highest form of any cancer among male patients in Brazil and most cases, in fact, point to BPH. More recently, increased vigilance on symptomatic manifestations encourages men to search for treatments or even pharmaceutical-based and minimally invasive surgical treatments. Access to health care in Brazil and Mexico, for example, is expanding further, creating more room for market expansion. Local pharmaceutical firms and multinational players are also taking advantage of this trend to present a myriad of treatment options specific to the regional market.

Middle East and Africa Benign Prostatic Hyperplasia Treatment Market

The BPH market in the Middle East and Africa is set to grow based on the area's increasing aging population and growing attention to prostate care. According to the NIH, the prevalence rate of BPH in the Middle East ranges between 13.84% to 23.79%. In this regard, the variation was due to some demographic factors across the region in addition to differing access to care. As the male population aged above 50 continues to climb, BPH treatments remain in demand. Improving healthcare regimes in the form of better diagnosis rates are being recorded in Saudi Arabia and South Africa. Local players have scaled up their activities both on the medical and the surgical side, while international pharmaceutical majors have positioned themselves in the market. Increased attention on BPH management in both the public and private sectors is expected to spur major growth in the market over the next few years.

Competitive Landscape:

The benign prostatic hyperplasia (BPH) treatment market is highly competitive with numerous pharmaceutical and medical device companies offering a wide range of solutions from medications to minimally invasive procedures. Companies are focusing on innovation such as developing advanced drug formulations with improved efficacy and fewer side effects as well as refining minimally invasive techniques like laser therapies and robotic-assisted surgeries. The market is also seeing significant investment in clinical trials and the development of combination therapies to enhance treatment outcomes. Strategic partnerships, mergers and acquisitions are common enabling companies to expand their product portfolios and geographic reach.

The report provides a comprehensive analysis of the competitive landscape in the benign prostatic hyperplasia treatment market with detailed profiles of all major companies, including:

  • Abbott Laboratories
  • Allergan Plc (AbbVie Inc.)
  • Asahi Kasei Corporation
  • Astellas Pharma Inc.
  • Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
  • Boston Scientific Corporation
  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1.How big is the benign prostatic hyperplasia treatment market?
  • 2.What are the market drivers for benign prostatic hyperplasia (BHP) treatment devices?
  • 3.What is the benign prostatic hyperplasia (BPH) treatment device market growth?
  • 4.What are the key factors driving the benign prostatic hyperplasia treatment market?
  • 5.Which region accounts for the largest benign prostatic hyperplasia treatment market share?
  • 6.Which are the leading companies in the global benign prostatic hyperplasia treatment market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Benign Prostatic Hyperplasia Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Treatment Type

  • 6.1 Drug Class
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Alpha-Blockers
      • 6.1.2.2 5-Alpha-reductase Inhibitors (5-ARIs)
      • 6.1.2.3 Phosphodiesterase-5 Enzyme Inhibitors
      • 6.1.2.4 Others
    • 6.1.3 Market Forecast
  • 6.2 Minimally Invasive Surgeries
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Transurethral Resection of the Prostate (TURP)
      • 6.2.2.2 Transurethral Incision of the Prostate (TUIP)
      • 6.2.2.3 Transurethral Microwave Thermotherapy (TUMT)
      • 6.2.2.4 Robotic Surgeries
      • 6.2.2.5 Prostatic Urethral Lifts
      • 6.2.2.6 Others
    • 6.2.3 Market Forecast
  • 6.3 Laser Therapy
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Others
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast

7 Market Breakup by Region

  • 7.1 North America
    • 7.1.1 United States
      • 7.1.1.1 Market Trends
      • 7.1.1.2 Market Forecast
    • 7.1.2 Canada
      • 7.1.2.1 Market Trends
      • 7.1.2.2 Market Forecast
  • 7.2 Asia Pacific
    • 7.2.1 China
      • 7.2.1.1 Market Trends
      • 7.2.1.2 Market Forecast
    • 7.2.2 Japan
      • 7.2.2.1 Market Trends
      • 7.2.2.2 Market Forecast
    • 7.2.3 India
      • 7.2.3.1 Market Trends
      • 7.2.3.2 Market Forecast
    • 7.2.4 South Korea
      • 7.2.4.1 Market Trends
      • 7.2.4.2 Market Forecast
    • 7.2.5 Australia
      • 7.2.5.1 Market Trends
      • 7.2.5.2 Market Forecast
    • 7.2.6 Indonesia
      • 7.2.6.1 Market Trends
      • 7.2.6.2 Market Forecast
    • 7.2.7 Others
      • 7.2.7.1 Market Trends
      • 7.2.7.2 Market Forecast
  • 7.3 Europe
    • 7.3.1 Germany
      • 7.3.1.1 Market Trends
      • 7.3.1.2 Market Forecast
    • 7.3.2 France
      • 7.3.2.1 Market Trends
      • 7.3.2.2 Market Forecast
    • 7.3.3 United Kingdom
      • 7.3.3.1 Market Trends
      • 7.3.3.2 Market Forecast
    • 7.3.4 Italy
      • 7.3.4.1 Market Trends
      • 7.3.4.2 Market Forecast
    • 7.3.5 Spain
      • 7.3.5.1 Market Trends
      • 7.3.5.2 Market Forecast
    • 7.3.6 Russia
      • 7.3.6.1 Market Trends
      • 7.3.6.2 Market Forecast
    • 7.3.7 Others
      • 7.3.7.1 Market Trends
      • 7.3.7.2 Market Forecast
  • 7.4 Latin America
    • 7.4.1 Brazil
      • 7.4.1.1 Market Trends
      • 7.4.1.2 Market Forecast
    • 7.4.2 Mexico
      • 7.4.2.1 Market Trends
      • 7.4.2.2 Market Forecast
    • 7.4.3 Others
      • 7.4.3.1 Market Trends
      • 7.4.3.2 Market Forecast
  • 7.5 Middle East and Africa
    • 7.5.1 Market Trends
    • 7.5.2 Market Breakup by Country
    • 7.5.3 Market Forecast

8 SWOT Analysis

  • 8.1 Overview
  • 8.2 Strengths
  • 8.3 Weaknesses
  • 8.4 Opportunities
  • 8.5 Threats

9 Value Chain Analysis

10 Porters Five Forces Analysis

  • 10.1 Overview
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Degree of Competition
  • 10.5 Threat of New Entrants
  • 10.6 Threat of Substitutes

11 Price Analysis

12 Competitive Landscape

  • 12.1 Market Structure
  • 12.2 Key Players
  • 12.3 Profiles of Key Players
    • 12.3.1 Abbott Laboratories
      • 12.3.1.1 Company Overview
      • 12.3.1.2 Product Portfolio
      • 12.3.1.3 Financials
      • 12.3.1.4 SWOT Analysis
    • 12.3.2 Allergan plc (AbbVie Inc.)
      • 12.3.2.1 Company Overview
      • 12.3.2.2 Product Portfolio
      • 12.3.2.3 Financials
      • 12.3.2.4 SWOT Analysis
    • 12.3.3 Asahi Kasei Corporation
      • 12.3.3.1 Company Overview
      • 12.3.3.2 Product Portfolio
      • 12.3.3.3 Financials
      • 12.3.3.4 SWOT Analysis
    • 12.3.4 Astellas Pharma Inc.
      • 12.3.4.1 Company Overview
      • 12.3.4.2 Product Portfolio
      • 12.3.4.3 Financials
      • 12.3.4.4 SWOT Analysis
    • 12.3.5 Boehringer Ingelheim GmbH (C.H. Boehringer Sohn AG & Ko. KG)
      • 12.3.5.1 Company Overview
      • 12.3.5.2 Product Portfolio
      • 12.3.5.3 SWOT Analysis
    • 12.3.6 Boston Scientific Corporation
      • 12.3.6.1 Company Overview
      • 12.3.6.2 Product Portfolio
      • 12.3.6.3 Financials
      • 12.3.6.4 SWOT Analysis
    • 12.3.7 GlaxoSmithKline Plc
      • 12.3.7.1 Company Overview
      • 12.3.7.2 Product Portfolio
      • 12.3.7.3 Financials
      • 12.3.7.4 SWOT Analysis
    • 12.3.8 Pfizer Inc.
      • 12.3.8.1 Company Overview
      • 12.3.8.2 Product Portfolio
      • 12.3.8.3 Financials
      • 12.3.8.4 SWOT Analysis
    • 12.3.9 Sanofi S.A.
      • 12.3.9.1 Company Overview
      • 12.3.9.2 Product Portfolio
      • 12.3.9.3 Financials
      • 12.3.9.4 SWOT Analysis
    • 12.3.10 Teva Pharmaceutical Industries Ltd.
      • 12.3.10.1 Company Overview
      • 12.3.10.2 Product Portfolio
      • 12.3.10.3 Financials
      • 12.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Benign Prostatic Hyperplasia Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Treatment Type (in %), 2024
  • Figure 4: Global: Benign Prostatic Hyperplasia Treatment Market: Breakup by Region (in %), 2024
  • Figure 5: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 6: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 7: Global: Benign Prostatic Hyperplasia Treatment (Drug Class) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 8: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 9: Global: Benign Prostatic Hyperplasia Treatment (Minimally Invasive Surgeries) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 10: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Benign Prostatic Hyperplasia Treatment (Laser Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Benign Prostatic Hyperplasia Treatment (Other Treatment Types) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: North America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: North America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: United States: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: United States: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Canada: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Canada: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Asia Pacific: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: China: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: China: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Japan: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Japan: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: India: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: India: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: South Korea: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: South Korea: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Australia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Australia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Indonesia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Indonesia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Europe: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Europe: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Germany: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Germany: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: France: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: France: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: United Kingdom: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: United Kingdom: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Italy: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Italy: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Spain: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Spain: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Russia: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Russia: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: Latin America: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: Latin America: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: Brazil: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: Brazil: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Mexico: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Mexico: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Others: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Others: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Country (in %), 2024
  • Figure 62: Middle East and Africa: Benign Prostatic Hyperplasia Treatment Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Global: Benign Prostatic Hyperplasia Treatment Industry: SWOT Analysis
  • Figure 64: Global: Benign Prostatic Hyperplasia Treatment Industry: Value Chain Analysis
  • Figure 65: Global: Benign Prostatic Hyperplasia Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Benign Prostatic Hyperplasia Treatment Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Treatment Type (in Million USD), 2025-2033
  • Table 3: Global: Benign Prostatic Hyperplasia Treatment Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 4: Global: Benign Prostatic Hyperplasia Treatment Market: Competitive Structure
  • Table 5: Global: Benign Prostatic Hyperplasia Treatment Market: Key Players